modelR03BA05

Extends from Pharmacokinetic.Models.PK_2C.

Information

name:Fluticasone
ATC code:R03BA05
route:inhalation
compartments:2
dosage:500mg
volume of distribution:4.2L
clearance:1.1L/min
other parameters in model implementation

Fluticasone is a synthetic corticosteroid used as an anti-inflammatory and immunosuppressive agent, primarily for the management of asthma and allergic rhinitis. Administered via inhalation, it reduces airway inflammation. Widely approved and in clinical use globally.

Pharmacokinetics

Pharmacokinetic parameters reported in healthy adult volunteers after inhaled administration.

References

  1. Soulele, K, et al., & Karalis, V (2015). Population pharmacokinetics of fluticasone propionate/salmeterol using two different dry powder inhalers. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 80 33–42. DOI:10.1016/j.ejps.2015.08.009 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26296862

  2. Siederer, S, et al., & Yang, S (2016). Population Pharmacokinetics of Inhaled Fluticasone Furoate and Vilanterol in Subjects with Chronic Obstructive Pulmonary Disease. European journal of drug metabolism and pharmacokinetics 41(6) 743–758. DOI:10.1007/s13318-015-0303-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26474864

  3. Allen, A, et al., & Yang, S (2016). Population pharmacokinetics of inhaled fluticasone furoate and vilanterol in adult and adolescent patients with asthma. International journal of clinical pharmacology and therapeutics 54(4) 269–281. DOI:10.5414/CP202438 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26902504

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)